Brand VerifiedChina

China Animal Husbandry Industry Co., Ltd.

CAHIC

CAHIC (China Animal Husbandry Industry Co., Ltd.) is China's state-owned backbone enterprise in the animal health sector, representing the country's largest domestically-controlled veterinary pharmaceutical platform. Founded in 1998 and headquartered in Beijing, China, CAHIC generated CNY 6.205 billion (~USD 860 million) in 2025 revenue, employing approximately 5,000 employees across multiple GMP manufacturing bases. With 2025 operating cash flow surging 175.89% to CNY 1.158 billion, CAHIC possesses extraordinary financial firepower for its strategic pivot from traditional livestock vaccines into the high-margin companion animal pharmaceutical market.

Strengths:
• State-Backed Financial Strength: CNY 1.158 billion in operating cash flow (up 175.89% YoY in 2025) provides ample capital for acquisitions and in-house companion animal product development
• API-to-Formulation Integration: Deep vertical integration from active pharmaceutical ingredients to finished vaccines and formulations, with multiple GMP-certified manufacturing bases
• Domestic Market Dominance: As China's state-owned animal health flagship, CAHIC controls significant market share in mandatory livestock vaccines and veterinary pharmaceuticals
• R&D Investment Scale: CNY 178 million in 2025 R&D expenditure, increasingly directed toward companion animal vaccines and therapeutics
• Regulatory Privilege: State-owned enterprise status provides preferential access to government procurement contracts and accelerated regulatory approvals in China
Weaknesses:
• Minimal Current Pet Portfolio: Companion animal products currently represent a negligible share of total revenue; the pivot to pet healthcare is aspirational rather than realized
• Livestock Cycle Dependency: Core revenue remains tied to volatile Chinese swine and poultry production cycles, with 2025 adjusted net profit declining 67.42% due to industry headwinds
• International Presence Gap: Operations remain overwhelmingly China-centric, with limited brand recognition or regulatory approvals in North American and European markets

Business Nature

CAHIC operates as a state-owned backbone enterprise in China's animal health sector with deep vertical integration from active pharmaceutical ingredients API to finished formulations and vaccines. The company possesses multiple large-scale GMP-certified manufacturing bases strategically distributed across China, covering API synthesis, biological fermentation, sterile filling, and solid dosage forms.

While historically focused on livestock vaccines and pharmaceutical raw materials categories 2.17 and 10.1, CAHIC is aggressively pivoting toward the companion animal market, leveraging its massive idle fermentation capacity and state-backed R&D funding CNY 178 million in 2025. The company generated an impressive CNY 1.158 billion in operating cash flow in 2025 up 175.89% YoY, providing ample firepower for acquisitions or in-house development in the high-margin pet pharmaceutical segment.

Core Business Areas

Animal Health Portfolio — Core Business
• Veterinary Vaccines: livestock mandatory vaccines / companion animal vaccines in development
• Active Pharmaceutical Ingredients: antibiotics / antiparasitics
• Feed Additives & Premixes
• Veterinary Chemical Drugs
• Diagnostic Reagents

Industry Rankings

9Top 10 Veterinary Pharmaceuticals & Pet Healthcare Companies

Brand

Corporate Report

CAHIC (China Animal Husbandry Industry Co., Ltd.) is a China-based state-owned animal health enterprise headquartered in Beijing. Founded in 1998 as China's national champion in veterinary pharmaceuticals. In 2025, CAHIC generated CNY 6.205 billion (~USD 860 million) in revenue, employing approximately 5,000 people across multiple GMP-certified manufacturing bases throughout China.

Core Business

CAHIC's traditional strength lies in mandatory livestock vaccines and pharmaceutical raw materials (API), where it serves as a critical supplier to China's massive swine and poultry industries. The company's API-to-formulation vertical integration spans antibiotic synthesis, biological fermentation, sterile injectable filling, and oral solid dosage manufacturing. Recognizing the structural decline in livestock sector margins, CAHIC is actively investing CNY 178 million in R&D (2025) to develop companion animal vaccines and therapeutics, leveraging its existing massive fermentation capacity.

Global Presence

CAHIC's operations are predominantly concentrated in China, where its multiple GMP manufacturing bases form a comprehensive national supply network. While international expansion remains nascent, the company's state-owned enterprise status and access to preferential government financing position it uniquely for accelerated global growth. The 2025 operating cash flow of CNY 1.158 billion (up 175.89% YoY) provides substantial capital for potential international acquisitions or in-licensing partnerships to fast-track companion animal market entry.

Key Strengths

• State-owned enterprise with CNY 1.158 billion in 2025 operating cash flow (up 175.89%)
• Complete API-to-formulation vertical integration across multiple GMP manufacturing bases
• CNY 178 million annual R&D investment increasingly directed toward companion animal products
• Dominant position in China's mandatory livestock vaccine market
• Government-backed financial and regulatory support enabling aggressive strategic pivots

VerityRank Score

VerityRank Score of 88/100

VerityRank Score

88/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Beijing, China

Founded

1998

Employees

5,000

Factories

Multiple large-scale GMP manufacturing bases across China

Listing

SSE: 600195

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website SSE: 600195 , CAHIC Official Website
Shanghai Stock Exchange — CAHIC (600195)
Wikipedia — CAHIC

Back to Rankings